These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17534973)

  • 1. Palivizumab prophylaxis: how to compare pre- and post-prophylaxis eras?
    Korppi M
    Pediatr Pulmonol; 2007 Jul; 42(7):660; author reply 661. PubMed ID: 17534973
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prevention of respiratory syncytial virus infections with palivizumab].
    Ellingsen BB; Aase SA; Øymar K
    Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
    Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
    Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
    Grimaldi M; Gouyon B; Sagot P; Quantin C; Huet F; Gouyon JB;
    Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Guidelines for respiratory syncytial virus prophylaxis. An update].
    Carbonell-Estrany X; Quero Jiménez J
    An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of an interventional program on adherence to the american academy of pediatrics guidelines for palivizumab prophylaxis.
    Afghani B; Ngo T; Leu SY; Wu FL; Cecilio M; Aron-Johnson P; Zeitany R; Sills J; Amin A
    Pediatr Infect Dis J; 2006 Nov; 25(11):1019-24. PubMed ID: 17072124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prophylaxis of respiratory syncytial virus infections with palivizumab].
    Danés Carreras I; Arnau De Bolós JM
    An Esp Pediatr; 2002 Apr; 56(4):289-91. PubMed ID: 11927094
    [No Abstract]   [Full Text] [Related]  

  • 8. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden.
    Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
    Acta Paediatr; 2004 Nov; 93(11):1470-3. PubMed ID: 15513574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current news about epidemiology of syncytial respiratory virus infection].
    Palumbo E
    Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA
    Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting.
    Manzoni P; Leonessa M; Farina D; Gomirato G
    Pediatr Transplant; 2007 Jun; 11(4):456-7. PubMed ID: 17493231
    [No Abstract]   [Full Text] [Related]  

  • 13. Prophylaxis against respiratory syncytial virus in premature infants. IMpact-RSV Study Group.
    Top FH; Connor EM; Carlin DA
    Lancet; 2000 Mar; 355(9208):1014. PubMed ID: 10768456
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.
    Speer ME; Fernandes CJ; Boron M; Groothuis JR
    Pediatr Infect Dis J; 2008 Jun; 27(6):559-61. PubMed ID: 18434935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab.
    Gupta D; Gupta P
    Indian Pediatr; 2001 Nov; 38(11):1265-9. PubMed ID: 11721066
    [No Abstract]   [Full Text] [Related]  

  • 16. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody.
    DeVincenzo JP; Aitken J; Harrison L
    J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small budget impact is a result of flawed assumptions and ignores questionable cost-effectiveness for RSV prophylaxis.
    Hampp C; Kauf TL; Winterstein AG
    Value Health; 2010 Aug; 13(5):684. PubMed ID: 20412545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.